CR20190313A - Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip - Google Patents
Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gipInfo
- Publication number
- CR20190313A CR20190313A CR20190313A CR20190313A CR20190313A CR 20190313 A CR20190313 A CR 20190313A CR 20190313 A CR20190313 A CR 20190313A CR 20190313 A CR20190313 A CR 20190313A CR 20190313 A CR20190313 A CR 20190313A
- Authority
- CR
- Costa Rica
- Prior art keywords
- glucagon
- gip
- receptor agonists
- peptidic
- gip receptor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16306604 | 2016-12-02 | ||
| PCT/EP2017/081125 WO2018100134A1 (en) | 2016-12-02 | 2017-12-01 | New compounds as peptidic trigonal glp1/glucagon/gip receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190313A true CR20190313A (es) | 2019-09-11 |
Family
ID=57542935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190313A CR20190313A (es) | 2016-12-02 | 2017-12-01 | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US10538567B2 (es) |
| EP (1) | EP3548508B1 (es) |
| JP (1) | JP7100033B2 (es) |
| KR (1) | KR102576872B1 (es) |
| CN (1) | CN110023329B (es) |
| AR (1) | AR110300A1 (es) |
| AU (1) | AU2017367173B2 (es) |
| BR (1) | BR112019011228A2 (es) |
| CA (1) | CA3045377A1 (es) |
| CL (1) | CL2019001465A1 (es) |
| CO (1) | CO2019006917A2 (es) |
| CR (1) | CR20190313A (es) |
| DO (1) | DOP2019000068A (es) |
| EA (1) | EA201991345A1 (es) |
| EC (1) | ECSP19046893A (es) |
| IL (1) | IL266984A (es) |
| MA (1) | MA46955A (es) |
| MX (1) | MX2019006429A (es) |
| PE (1) | PE20191143A1 (es) |
| PH (1) | PH12019501216A1 (es) |
| TW (1) | TW201833132A (es) |
| UY (1) | UY37506A (es) |
| WO (1) | WO2018100134A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201833132A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物 |
| AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
| KR20200142033A (ko) | 2018-04-10 | 2020-12-21 | 사노피-아벤티스 도이칠란트 게엠베하 | 고체상으로부터 고체상-결합된 펩타이드를 절단하는 방법 |
| KR20200142032A (ko) | 2018-04-10 | 2020-12-21 | 사노피-아벤티스 도이칠란트 게엠베하 | 캡핑을 사용한 릭시세나티드 합성 |
| UY38249A (es) | 2018-05-30 | 2019-12-31 | Sanofi Sa | Productos conjugados que comprenden un agonista del receptor triple de glp-1/glucagón/gip, un conector y ácido hialurónico |
| US20230000950A1 (en) * | 2019-10-04 | 2023-01-05 | Hanmi Pharm. Co., Ltd. | Composition comprising glucagon and glp-1 and gip receptor dual agonist and therapeutic use of same |
| CA3156452A1 (en) | 2019-11-11 | 2021-05-20 | Boehringer Ingelheim International Gmbh | NPY2 RECEPTOR AGONISTS |
| KR20230045088A (ko) | 2020-08-07 | 2023-04-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 가용성 npy2 수용체 작용제 |
| MX2023001601A (es) * | 2020-08-14 | 2023-03-07 | Hanmi Pharmaceutical Co Ltd | Composicion farmaceutica hipotensora que comprende un activador triple que tiene actividad para todos los receptores de glucagon, glp-1, y gip. |
| CN114349828B (zh) * | 2020-11-27 | 2023-12-08 | 江苏师范大学 | Glp-1/胰高血糖素受体双重激动剂及其应用 |
| MX2023006281A (es) * | 2020-12-16 | 2023-06-13 | Zealand Pharma As | Composicion farmaceutica de agonistas duales de glp-1/glp-2. |
| BR112023025387A2 (pt) * | 2021-06-25 | 2024-02-27 | Lilly Co Eli | Usos de tirzepatida |
| KR20230004135A (ko) * | 2021-06-30 | 2023-01-06 | 한미약품 주식회사 | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도 |
| TW202404997A (zh) * | 2022-05-27 | 2024-02-01 | 韓商Ｄ＆Ｄ製藥科技股份有限公司 | 肽組合物及其使用方法 |
| WO2024067662A1 (zh) * | 2022-09-28 | 2024-04-04 | 广东东阳光药业股份有限公司 | Glp-1/gcg/gip三受体激动剂及其用途 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1546200A2 (en) | 2002-10-02 | 2005-06-29 | Zealand Pharma A/S | Stabilized exendin-4 compounds |
| US20080019911A1 (en) * | 2005-04-20 | 2008-01-24 | Aimin Xu | Method for decreasing blood glucose and improving glucose tolerance using angiopoietin-like protein 4 |
| AU2006258841B2 (en) | 2005-06-13 | 2012-05-03 | Imperial Innovations Limited | Oxyntomodulin analogues and their effects on feeding behaviour |
| ES2650038T3 (es) | 2008-06-17 | 2018-01-16 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
| JP5887265B2 (ja) | 2009-06-16 | 2016-03-16 | インディアナ・ユニバーシティ・リサーチ・アンド・テクノロジー・コーポレーション | Ｇｉｐ受容体活性グルカゴン化合物 |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| EA201390941A1 (ru) | 2010-12-22 | 2013-12-30 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Аналоги глюкагона, проявляющие активность на рецепторе gip |
| SG11201408491SA (en) | 2012-06-21 | 2015-01-29 | Univ Indiana Res & Tech Corp | Analogs of glucagon exhibiting gip receptor activity |
| MX2014015558A (es) | 2012-06-21 | 2015-03-05 | Univ Indiana Res & Tech Corp | Analogos de glucagon que exhiben actividad del receptor gip. |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| UA116553C2 (uk) * | 2012-12-21 | 2018-04-10 | Санофі | Пептидна сполука - агоніст рецептора glp-1 i glp |
| CA2929107C (en) * | 2013-11-06 | 2023-09-26 | Zealand Pharma A/S | Glucagon-glp-1-gip triple agonist compounds |
| EP3080151A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Exendin-4 peptide analogues |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| WO2015086731A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| TW201625670A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| TW201833132A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物 |
| AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
-
2017
- 2017-11-30 TW TW106141759A patent/TW201833132A/zh unknown
- 2017-11-30 AR ARP170103362A patent/AR110300A1/es unknown
- 2017-12-01 MX MX2019006429A patent/MX2019006429A/es unknown
- 2017-12-01 CA CA3045377A patent/CA3045377A1/en not_active Abandoned
- 2017-12-01 WO PCT/EP2017/081125 patent/WO2018100134A1/en unknown
- 2017-12-01 EP EP17821804.6A patent/EP3548508B1/en active Active
- 2017-12-01 KR KR1020197018943A patent/KR102576872B1/ko active IP Right Grant
- 2017-12-01 CR CR20190313A patent/CR20190313A/es unknown
- 2017-12-01 BR BR112019011228A patent/BR112019011228A2/pt not_active Application Discontinuation
- 2017-12-01 JP JP2019529535A patent/JP7100033B2/ja active Active
- 2017-12-01 MA MA046955A patent/MA46955A/fr unknown
- 2017-12-01 UY UY0001037506A patent/UY37506A/es unknown
- 2017-12-01 AU AU2017367173A patent/AU2017367173B2/en active Active
- 2017-12-01 PE PE2019000905A patent/PE20191143A1/es unknown
- 2017-12-01 CN CN201780074707.9A patent/CN110023329B/zh active Active
- 2017-12-01 US US15/829,680 patent/US10538567B2/en active Active
- 2017-12-01 EA EA201991345A patent/EA201991345A1/ru unknown
-
2019
- 2019-03-19 DO DO2019000068A patent/DOP2019000068A/es unknown
- 2019-05-29 IL IL266984A patent/IL266984A/en unknown
- 2019-05-30 CL CL2019001465A patent/CL2019001465A1/es unknown
- 2019-05-31 PH PH12019501216A patent/PH12019501216A1/en unknown
- 2019-06-27 CO CONC2019/0006917A patent/CO2019006917A2/es unknown
- 2019-07-01 EC ECSENADI201946893A patent/ECSP19046893A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20180155406A1 (en) | 2018-06-07 |
| MA46955A (fr) | 2021-05-19 |
| BR112019011228A2 (pt) | 2019-10-15 |
| AU2017367173B2 (en) | 2022-03-24 |
| CL2019001465A1 (es) | 2019-10-18 |
| PH12019501216A1 (en) | 2019-08-19 |
| JP7100033B2 (ja) | 2022-07-12 |
| CA3045377A1 (en) | 2018-06-07 |
| JP2019536796A (ja) | 2019-12-19 |
| KR102576872B1 (ko) | 2023-09-12 |
| ECSP19046893A (es) | 2019-07-31 |
| UY37506A (es) | 2018-06-29 |
| AR110300A1 (es) | 2019-03-13 |
| EP3548508A1 (en) | 2019-10-09 |
| CO2019006917A2 (es) | 2019-07-10 |
| PE20191143A1 (es) | 2019-09-02 |
| US10538567B2 (en) | 2020-01-21 |
| CN110023329A (zh) | 2019-07-16 |
| EP3548508B1 (en) | 2021-10-27 |
| KR20190085141A (ko) | 2019-07-17 |
| CN110023329B (zh) | 2024-05-03 |
| AU2017367173A1 (en) | 2019-07-18 |
| WO2018100134A1 (en) | 2018-06-07 |
| TW201833132A (zh) | 2018-09-16 |
| IL266984A (en) | 2019-07-31 |
| MX2019006429A (es) | 2019-08-21 |
| DOP2019000068A (es) | 2019-05-31 |
| EA201991345A1 (ru) | 2019-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20190313A (es) | Nuevos compuestos como agonistas peptídicos trigonales de los receptores de glp1/glucagón/gip | |
| AR099977A1 (es) | Agonistas peptídicos dobles de los receptores del péptido similar al glucagón 1 (glp-1) y del receptor del glucagón (gcg), derivados de la exendina-4 | |
| UY36779A (es) | Nuevos derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón | |
| UY35231A (es) | Agonistas duales de GLP1/GIP o trigonales de GLP1/GIP/Glucagón | |
| MX2016013244A (es) | Derivados de exendina-4 como agonistas peptidicos duales del receptor de glp-1/glucagon. | |
| AR098741A1 (es) | Agonistas duales del receptor de glp-1 (péptido similar al glucagón 1) / glucagón | |
| BR112019011144A2 (pt) | compostos como agonistas peptídicos de receptor de glp1/glucagon/gip | |
| UY35072A (es) | Derivados de exendina-4 como agonistas duales de GLP1/glucagón | |
| MX2016013248A (es) | Agonistas duales del receptor de glp-1/glucagon derivados de exendina-4. | |
| CL2017001760A1 (es) | Compuestos co-agonistas de gip y glp-1 | |
| AR098738A1 (es) | Análogos del péptido exendina-4 no acilados | |
| AR091422A1 (es) | Analogos peptidicos de la exendina 4 | |
| AR102712A1 (es) | Agonistas parciales del receptor de insulina | |
| CR20170376A (es) | Tratamiento de pacientes pediátricos con diabetes mellitus de tipo 2 con lixisenatida | |
| CR20170470A (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 | |
| AR103944A1 (es) | Tratamiento de pacientes con diabetes mellitus tipo 2 |